HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir

Journal of Clinical Investigation

Volumn 115, Issue 11, 2005, Pages 3250-3255

  Chun, Tae Wook ^a   Nickle, David C ^b   Justement, J Shawn ^a   Large, Danielle ^a   Semerjian, Alice ^a   Curlin, Marcel E ^b   O'Shea, M Angeline ^a   Hallahan, Claire W ^a   Daucher, Marybeth ^a   Ward, Douglas J ^c   Moir, Susan ^a   Mullins, James I ^b   Kovacs, Colin ^d   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Dupont Circle Physicians Group   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; TENOFOVIR; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS INFECTION; DNA SEQUENCE; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; LYMPHOCYTE COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PERSISTENT VIRUS INFECTION; PHYLOGENY; PRIORITY JOURNAL; PROVIRUS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRION; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; TIME FACTORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 27644524761     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI26197     Document Type: Article

References (36)

1. Department of Health and Human Services Public Health Service. 2000. HIV/AIDS surveillance report. Centers for Disease Control and Prevention. 12:1-44.
2. Chun, T.W., et al. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:13193-13197.
3. Finzi, D., et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1295-1300.
4. Wong, J.K., et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1291-1295.
5. Siliciano, J.D., et al. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
6. Zhang, L., et al. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
7. Furtado, M.R., et al. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N. Engl. J. Med. 340:1614-1622.
8. Hermankova, M., et al. 2003. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J. Virol. 77:7383-7392.
9. Chun, T.W., et al. 2000. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 6:757-761.
10. Ramratnam, B., et al. 2000. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med. 6:82-85.
11. Zhu, T., et al. 2002. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J. Virol. 76:707-716.
12. Ramratnam, B., et al. 2004. Intensification of anti-retroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J. Acquir. Immune. Defic. Syndr. 35:33-37.
13. Sharkey, M.E., et al. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 6:76-81.
14. Sharkey, M., Triques, K., Kuritzkes, D.R., and Stevenson, M. 2005. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 79:5203-5210.
15. Natarajan, V., et al. 1999. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 353:119-120.
16. Patterson, B.K., et al. 2001. Persistence of intracellular HIV-1 mRNA correlates with HIV-1-specific immune responses in infected subjects on stable HAART. AIDS. 15:1635-1641.
17. Havlir, D.V., et al. 2003. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 77:11212-11219.
18. Chun, T.W., et al. 2003. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc. Natl. Acad. Sci. U. S. A. 100:1908-1913.
19. Thompson, J.D., Higgins, D.G., and Gibson, T.J. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
20. Huelsenbeck, J.P., and Crandall, K.A. 1997. Phylogeny estimation and hypothesis testing using maximum likelihood. Annu. Rev. Ecol. Syst. 28:437-466.
21. Huelsenbeck, J.P., and Rannala, B. 1997. Phylogenetic methods come of age: testing hypotheses in an evolutionary context. Science. 276:227-232.
22. Posada, D., and Crandall, K.A. 1998. MODEL-TEST: testing the model of DNA substitution. Bioinformatics. 14:817-818.
23. Slatkin, M., and Maddison, W.P. 1989. A cladistic measure of gene flow inferred from the phylogenies of alleles. Genetics. 123:603-613.
24. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1582-1586.
25. Perelson, A.S., et al. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 387:188-191.
26. Bukrinsky, M.I., Stanwick, T.L., Dempsey, M.P., and Stevenson, M. 1991. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science. 254:423-427.
27. Chun, T.W., et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:183-188.
28. Chun, T.W., and Fauci, A.S. 1999. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U. S. A. 96:10958-10961.
29. Zhang, L., et al. 2000. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J. Clin. Invest. 106:839-845.
30. Kulkosky, J., et al. 2002. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J. Infect. Dis. 186:1403-1411.
31. Wang, F.X., et al. 2005. IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J. Clin. Invest. 115:128-137. doi:10.1172/JCI200522574.
32. Stanley, S.K., et al. 1996. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334:1222-1230.
33. Chun, T.W., Engel, D., Mizell, S.B., Ehler, L.A., and Fauci, A.S. 1998. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J. Exp. Med. 188:83-91.
34. Chapuis, A.G., et al. 2000. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med. 6:762-768.
35. Chun, T.W., et al. 1998. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 95:8869-8873.
36. Chun, T.W., et al. 1999. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat. Med. 5:651-655.